News

Ranbaxy Laboratories (Ranbaxy) has obtained FDA approval in the US to market its over-the-counter drug, Acetaminophen tablets. The company said that the tablets will be available in 650mg,

Glycotope has received regulatory approval by Germany and Italian regulatory authorities for a Phase I study of Glycotope’s lead antibody GT-MAB 2.5-GEX for the treatment of various solid

Advitech has reported that the TSX Venture Exchange (the TSX-V) has approved the previously announced consolidation of its issued and outstanding common shares on the basis of a

Takeda has submitted a supplemental new drug application to the Ministry of Health, Welfare and Labour in Japan for Takepron Capsules 15 and Takepron OD tablet 15 (lansoprazole)

Karo Bio has announced that Merck & Co. plans to enter a clinical phase IIa trial with the investigational drug candidate, MK-6913, identified as part of their joint

Merck & Co., through an affiliate, has extended its research collaboration with Idera for a fourth year. In December 2006, the companies entered into an exclusive license and

Genfit has reported positive results in Phase II trial with its most advanced drug candidate, GFT505, in prediabetic patients with atherogenic dyslipidemia and abdominal obesity (study GFT505-2083). The

Pfizer Japan (Pfizer) and Astellas Pharma (Astellas) to launch the combination drug of hypertension treatment and hypercholesterolemia treatment Caduet combination tablets (generic name: amlodipine besylate and atorvastatin calcium)

China Sky One Medical has recently passed the Chinese National Institute for the Control of Pharmaceutical and Biological Products (ICPBP) examination for two of its new products –